BMB Reports

Korean Society for Biochemistry and Molecular Biology (생화학분자생물학회)
권호 표지
DOI QR코드

DOI QR Code

SPINK1 promotes cell growth and metastasis of lung adenocarcinoma and acts as a novel prognostic biomarker

  • Xu, Liyun (Cell and Molecular Biology Laboratory, Affiliated Zhoushan Hospital of Wenzhou Medical University) ;
  • Lu, Changchang (Cell and Molecular Biology Laboratory, Affiliated Zhoushan Hospital of Wenzhou Medical University) ;
  • Huang, Yanyan (Cell and Molecular Biology Laboratory, Affiliated Zhoushan Hospital of Wenzhou Medical University) ;
  • Zhou, Jihang (Cell and Molecular Biology Laboratory, Affiliated Zhoushan Hospital of Wenzhou Medical University) ;
  • Wang, Xincheng (Cell and Molecular Biology Laboratory, Affiliated Zhoushan Hospital of Wenzhou Medical University) ;
  • Liu, Chaowu (Department of Cardio-Thoracic Surgery, Affiliated Zhoushan Hospital of Wenzhou Medical University) ;
  • Chen, Jun (Department of Cardio-Thoracic Surgery, Affiliated Zhoushan Hospital of Wenzhou Medical University) ;
  • Le, Hanbo (Department of Cardio-Thoracic Surgery, Affiliated Zhoushan Hospital of Wenzhou Medical University)
  • Received : 2018.09.04
  • Accepted : 2018.11.15
  • Published : 2018.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Serine protease inhibitor Kazal type 1 (SPINK1) plays a role in protecting the pancreas against premature activation of trypsinogen and is involved in cancer progression. SPINK1 promoted LAC cells growth, migration, and invasion. Mechanistically, we found that SPINK1 promoted LAC cells migration and invasion via up-regulating matrix metalloproteinase 12 (MMP12). We observed that SPINK1 expression was only up-regulated in lung adenocarcinoma (LAC) tissues, and was an independent prognostic factor for poor survival. Our results indicate that SPINK1 might be a potential biomarker for LAC that promotes progression by MMP12.

Keywords

References

  1. Paci E, Puliti D, Lopes Pegna A et al (2017) Mortality, survival and incidence rates in the ITALUNG randomized lung cancer screening trial. Thorax 72, 825-831 https://doi.org/10.1136/thoraxjnl-2016-209825
  2. Parkin DM, Bray F, Ferlay J et al (2002) Global cancer statistics. CA Cancer J Clin 55, 74-108
  3. Molina JR, Yang P, Cassivi SD et al (2008) Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 83, 584-594 https://doi.org/10.1016/S0025-6196(11)60735-0
  4. Stenman UH (2002) Tumor-associated trypsin inhibitor. Clin Chem 48, 1206-1209
  5. Itkonen O and Stenman UH (2014) TATI as a biomarker. Clin Chim Acta 431, 260-269 https://doi.org/10.1016/j.cca.2014.02.014
  6. Stenman UH, Huhtala ML, Koistinen R et al (1982) Immunochemical demonstration of an ovarian cancer-associated urinary peptide. Int J Cancer 30, 53-57 https://doi.org/10.1002/ijc.2910300110
  7. Scheving LA (1983) Primary amino acid sequence similarity between human epidermal growth factorurogastrone, human pancreatic secretory trypsin inhibitor, and members of porcine secretin family. Arch Biochem Biophys 226, 411-413 https://doi.org/10.1016/0003-9861(83)90309-0
  8. Ateeq B, Tomlins SA, Laxman B et al (2011) Therapeutic targeting of SPINK1-positive prostate cancer. Sci Transl 3, 72ra17
  9. Ida S, Ozaki N, Araki K et al (2015) SPINK1 status in colorectal cancer, impact on proliferation, and role in colitis-associated cancer. Mol Cancer Res 13, 1130-1138 https://doi.org/10.1158/1541-7786.MCR-14-0581
  10. Tiwari R, Pandey SK, Goel S et al (2015) SPINK1 promotes colorectal cancer progression by downregulating Metallothioneins expression. Oncogenesis 10, 4:e162
  11. Zhang J, Wang D, Hu N et al (2016) The construction and proliferative effects of a lentiviral vector capable of stably overexpressing SPINK1 gene in human pancreatic cancer AsPC-1 cell line. Tumour Biol 37, 5847-5855 https://doi.org/10.1007/s13277-015-4405-z
  12. Mehner C, Oberg AL, Kalli KR et al (2015) Serine protease inhibitor Kazal type 1 (SPINK1) drives proliferation and anoikis resistance in a subset of ovarian cancers. Oncotarget 6, 35737-35754
  13. Ateeq B, Tomlins SA, Laxman B et al (2011) Therapeutic targeting of SPINK1-positive prostate cancer. Sci Transl Med 3, 72ra17
  14. Chen YT, Tsao SC, Yuan SS et al (2015) Serine protease inhibitor Kazal type 1 (SPINK1) promotes proliferation of colorectal cancer through the epidermal growth factor as a prognostic marker. Pathol Oncol Res 21, 1201-1208 https://doi.org/10.1007/s12253-015-9949-0
  15. El-mezayen HA, Metwally FM and Darwish H (2014) A novel discriminant score based on tumor-associated trypsin inhibitor for accurate diagnosis of metastasis in patients with breast cancer. Tumour Biol 35, 2759-2767 https://doi.org/10.1007/s13277-013-1366-y
  16. Ozaki N, Ohmuraya M, Hirota M et al (2009) Serine protease inhibitor Kazal type 1 promotes proliferation of pancreatic cancer cells through the epidermal growth factor receptor. Mol Cancer Res 7, 1572-1581 https://doi.org/10.1158/1541-7786.MCR-08-0567
  17. Gaber A, Johansson M, Stenman UH et al (2009) High expression of tumour associated trypsin inhibitor correlates with liver metastasis and poor prognosis in colorectal cancer. Br J Cancer 100, 1540-1548 https://doi.org/10.1038/sj.bjc.6605047
  18. Tomlins SA, Rhodes DR, Yu J et al (2008) The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell 13, 519-528 https://doi.org/10.1016/j.ccr.2008.04.016
  19. Ying HY, Gong CJ, Feng Y et al (2017) Serine protease inhibitor Kazal type 1 (SPINK1) downregulates E-cadherin and induces EMT of hepatoma cells to promote hepatocellular carcinoma metastasis via the MEK/ERK signaling pathway. J Dig Dis 18, 349-358 https://doi.org/10.1111/1751-2980.12486
  20. Tania M, Khan MA and Fu J (2014) Epithelial to mesenchymal transition inducing transcription factors and metastatic cancer. Tumour Biol 35, 7335-7342 https://doi.org/10.1007/s13277-014-2163-y
  21. Chakraborti S, Mandal M, Das S et al (2003) Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem 253, 269-285 https://doi.org/10.1023/A:1026028303196
  22. O-charoenrat P, Modjtahedi H, Rhys-Evans P et al (2000) Epidermal growth factor-like ligands differentially up-regulate matrix metalloproteinase 9 in head and neck squamous carcinama cells. Cancer Res 60, 1121-1128
  23. Lv FZ, Wang JL, Wu Y et al (2015) Knockdown of MMP12 inhibits the growth and invasion of lung adenocarcinoma cells. Int J Immunopathol Pharmacol 28, 77-84 https://doi.org/10.1177/0394632015572557
  24. Flavin R, Pettersson A, Hendrickson WK et al (2014) SPINK1 protein expression and prostate cancer progression. Clin Cancer Res 20, 4904-4911 https://doi.org/10.1158/1078-0432.CCR-13-1341
  25. Zhang X, Yin X, Shen P et al (2017) The association between SPINK1 and clinical outcomes in patients with prostate cancer: a systematic review and meta-analysis. Onco Targets Ther 10, 3123-3130 https://doi.org/10.2147/OTT.S127317
  26. Rasanen K, Itkonen O, Koistinen H and Stenman UH (2016) Emerging Roles of SPINK1 in Cancer. Clin Chem 62, 449-457 https://doi.org/10.1373/clinchem.2015.241513